Coordinated Financial Services Inc. Buys New Shares in Stryker Co. (NYSE:SYK)

Coordinated Financial Services Inc. bought a new stake in shares of Stryker Co. (NYSE:SYK) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,748 shares of the medical technology company’s stock, valued at approximately $629,000.

Several other large investors have also recently bought and sold shares of SYK. United Community Bank raised its stake in shares of Stryker by 3.4% in the 4th quarter. United Community Bank now owns 904 shares of the medical technology company’s stock valued at $325,000 after buying an additional 30 shares in the last quarter. Amundi raised its stake in shares of Stryker by 1.1% in the 4th quarter. Amundi now owns 807,434 shares of the medical technology company’s stock valued at $293,987,000 after buying an additional 9,114 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its stake in shares of Stryker by 1.1% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 5,554 shares of the medical technology company’s stock valued at $2,000,000 after buying an additional 58 shares in the last quarter. Rialto Wealth Management LLC acquired a new stake in shares of Stryker during the 4th quarter worth about $1,205,000. Finally, Larson Financial Group LLC increased its position in shares of Stryker by 5.0% during the 4th quarter. Larson Financial Group LLC now owns 10,294 shares of the medical technology company’s stock worth $3,706,000 after purchasing an additional 492 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

NYSE:SYK opened at $379.28 on Friday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a fifty day simple moving average of $382.45 and a 200 day simple moving average of $372.99. The stock has a market capitalization of $144.73 billion, a PE ratio of 48.88, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the firm earned $3.46 earnings per share. On average, research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on SYK shares. JPMorgan Chase & Co. increased their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Truist Financial lifted their price objective on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Finally, Canaccord Genuity Group raised their target price on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.